Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

I have a specific set of rules that need to ... is likely to wait until after a new administration takes office. If the decision doesn't go in Novo Nordisk's favor, I believe the market will ...

The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on ...

Bank of America Securities analyst Sachin Jain maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Obesity drug maker Novo Nordisk NVO-N forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as “good ...

BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too ... were implemented by the Inflation Reduction Act during the Biden administration, and their future is uncertain. "We don't have a lot of insight ...